[go: up one dir, main page]

NI201900086A - Anticuerpos humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo. - Google Patents

Anticuerpos humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo.

Info

Publication number
NI201900086A
NI201900086A NI201900086A NI201900086A NI201900086A NI 201900086 A NI201900086 A NI 201900086A NI 201900086 A NI201900086 A NI 201900086A NI 201900086 A NI201900086 A NI 201900086A NI 201900086 A NI201900086 A NI 201900086A
Authority
NI
Nicaragua
Prior art keywords
treat
cognitive disorders
prevent cognitive
agent
produce
Prior art date
Application number
NI201900086A
Other languages
English (en)
Inventor
Hiroshi Eguchi
Takashi Murakami
Tanokura Akira
E Baker Jeanne
PARMENTIER BATTEUR Sophie
Marie JABLONSKI Angela
Stephen MALASHOCK Daniel
Mieczkowski Carl
Raghunathan Gopalan
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of NI201900086A publication Critical patent/NI201900086A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención proporciona métodos para usar y composiciones de anticuerpos humanizados que se unen a la proteina tau que está fosforilada en la serina en la posición 413.
NI201900086A 2017-02-27 2019-08-09 Anticuerpos humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo. NI201900086A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017035594A JP2018139530A (ja) 2017-02-27 2017-02-27 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤

Publications (1)

Publication Number Publication Date
NI201900086A true NI201900086A (es) 2019-10-08

Family

ID=62025891

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201900086A NI201900086A (es) 2017-02-27 2019-08-09 Anticuerpos humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo.

Country Status (26)

Country Link
US (3) US10556950B2 (es)
EP (1) EP3585810B1 (es)
JP (4) JP2018139530A (es)
KR (1) KR102701634B1 (es)
CN (2) CN111320695B (es)
AR (2) AR110875A1 (es)
AU (1) AU2018224390C1 (es)
BR (1) BR112019016490A2 (es)
CA (1) CA3052538A1 (es)
CL (3) CL2019002296A1 (es)
CO (1) CO2019008786A2 (es)
CR (1) CR20190363A (es)
DO (1) DOP2019000215A (es)
EA (1) EA201991726A1 (es)
GE (1) GEP20227392B (es)
IL (1) IL267945B2 (es)
JO (1) JOP20180014A1 (es)
MA (1) MA47608A (es)
MX (2) MX2019009945A (es)
MY (1) MY193821A (es)
NI (1) NI201900086A (es)
PE (2) PE20191614A1 (es)
PH (1) PH12019501929A1 (es)
SG (2) SG10201913419TA (es)
TW (2) TWI848904B (es)
WO (2) WO2018154392A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20192267T1 (hr) * 2012-05-31 2020-03-20 Osaka City University Terapeutski agens ili profilaktički agens za demenciju
JP2020508054A (ja) 2017-02-17 2020-03-19 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 抗タウ抗体及びその使用方法
JOP20180014A1 (ar) * 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه
US10829547B2 (en) 2017-10-16 2020-11-10 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
US20210355199A1 (en) 2018-06-28 2021-11-18 University Of Virginia Patent Foundation Compositions and methods for detecting and regulating fibronectin-integrin interaction and signaling
US12365724B2 (en) * 2018-12-10 2025-07-22 New York University Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof
EP3924464A4 (en) 2019-02-11 2022-11-23 University of Virginia Patent Foundation SELECTION AND BLOCKING OF MALE AND FEMALE GAMETES SUITABLE FOR FERTILIZATION
WO2020186247A1 (en) 2019-03-13 2020-09-17 University Of Virginia Patent Foundation Compositions and methods for promoting islet viability and enhancing insulin secretion
TWI832183B (zh) * 2019-08-06 2024-02-11 香港商新旭生技股份有限公司 結合至病理性tau種類之抗體及其用途
IL296519A (en) * 2020-06-02 2022-11-01 Teijin Pharma Ltd Anti-igf-1 receptor humanized antibody
MX2022016322A (es) * 2020-06-25 2023-01-24 Merck Sharp & Dohme Llc Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413.
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN115322255B (zh) * 2022-04-25 2025-03-07 上海药明生物医药有限公司 一种优化的Fc变体及其应用
CN120019071A (zh) 2022-09-15 2025-05-16 沃雅戈治疗公司 Tau结合化合物
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN119080924B (zh) * 2024-07-04 2025-02-25 上海交通大学医学院附属第九人民医院 一种单克隆免疫球蛋白及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS587390B2 (ja) 1975-03-11 1983-02-09 ツキシマキカイ カブシキガイシヤ ア−クヨウセツホウホウ
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
JP3587390B2 (ja) 1994-03-17 2004-11-10 タカラバイオ株式会社 リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法
US7657380B2 (en) 2003-12-04 2010-02-02 Xencor, Inc. Methods of generating variant antibodies with increased host string content
WO2005022156A1 (ja) 2003-08-29 2005-03-10 Reverse Proteomics Research Institute Co., Ltd. タンパク質の固定化方法
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
WO2012045882A2 (en) 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition
CN103339146B (zh) 2010-10-11 2017-09-01 比奥根国际神经科学公司 人抗tau抗体
EP3578567A1 (en) 2011-12-20 2019-12-11 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
HRP20192267T1 (hr) 2012-05-31 2020-03-20 Osaka City University Terapeutski agens ili profilaktički agens za demenciju
JP6290212B2 (ja) * 2012-08-16 2018-03-07 アイピエリアン，インコーポレイティド タウオパチーの処置方法
EP3792278A3 (en) 2012-12-21 2021-05-26 Biogen MA Inc. Human anti-tau antibodies
BR112015030356A2 (pt) 2013-06-10 2017-12-05 Ipierian Inc métodos de tratamento de uma taupatia
MX2016007208A (es) 2013-12-20 2016-07-21 Hoffmann La Roche Anticuerpos anti-tau(ps422) humanizados y metodos de uso.
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TW202136296A (zh) * 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
KR20170080675A (ko) 2014-11-05 2017-07-10 제넨테크, 인크. 항-fgfr2/3 항체 및 이의 이용 방법
WO2016112078A2 (en) 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
EA036821B1 (ru) 2015-07-06 2020-12-23 Юсб Биофарма Срл Тау-связывающие антитела
MX2017015817A (es) 2015-07-06 2018-04-10 Ucb Biopharma Sprl Anticuerpos de union a tau.
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
JOP20180014A1 (ar) 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه

Also Published As

Publication number Publication date
US20210380677A1 (en) 2021-12-09
AU2018224390A1 (en) 2019-07-11
AU2018224390B2 (en) 2024-10-31
US10894829B2 (en) 2021-01-19
MA47608A (fr) 2020-01-01
WO2018154390A1 (en) 2018-08-30
US11739143B2 (en) 2023-08-29
CA3052538A1 (en) 2018-08-30
EA201991726A1 (ru) 2020-01-30
IL267945A (en) 2019-09-26
TWI848904B (zh) 2024-07-21
JOP20180014A1 (ar) 2019-01-30
PE20191614A1 (es) 2019-11-05
TW201843179A (zh) 2018-12-16
WO2018154392A1 (en) 2018-08-30
IL267945B2 (en) 2025-10-01
AR110875A1 (es) 2019-05-08
CN111320695A (zh) 2020-06-23
DOP2019000215A (es) 2019-09-30
JP2020508666A (ja) 2020-03-26
MX2023013246A (es) 2023-11-21
BR112019016490A2 (pt) 2020-04-07
US20180346564A1 (en) 2018-12-06
US20200223916A1 (en) 2020-07-16
MY193821A (en) 2022-10-27
PH12019501929A1 (en) 2020-06-29
CO2019008786A2 (es) 2019-08-20
KR102701634B1 (ko) 2024-08-30
JP2023002670A (ja) 2023-01-10
GEP20227392B (en) 2022-06-27
EP3585810A1 (en) 2020-01-01
IL267945B1 (en) 2025-06-01
CN111320695B (zh) 2021-09-03
CL2024000339A1 (es) 2024-08-16
CN110382528A (zh) 2019-10-25
PE20241514A1 (es) 2024-07-19
SG10201913419TA (en) 2020-03-30
CL2021002389A1 (es) 2022-04-22
CL2019002296A1 (es) 2019-11-29
KR20190122674A (ko) 2019-10-30
EP3585810B1 (en) 2025-11-26
TW202506718A (zh) 2025-02-16
JP2018139530A (ja) 2018-09-13
JP7165996B2 (ja) 2022-11-07
CR20190363A (es) 2019-11-05
US10556950B2 (en) 2020-02-11
AU2018224390C1 (en) 2025-04-17
SG11201907548PA (en) 2019-09-27
MX2019009945A (es) 2019-11-05
AR117952A2 (es) 2021-09-08
JP2024170459A (ja) 2024-12-10

Similar Documents

Publication Publication Date Title
NI201900086A (es) Anticuerpos humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo.
CL2019001411A1 (es) Métodos para inhibición de la fibrosis en un sujeto en necesidad de ellos. (divisional solicitud 201801817)
CL2019003114A1 (es) Anticuerpos anti–tau y métodos de uso (divisional solicitud 201703063)
UY38407A (es) Anticuerpos estabilizadores de trem2
CL2020001391A1 (es) Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina.
EP3762031A4 (en) ANTI-CLAUDINE ANTIBODIES 18.2 AND THEIR USES
MX2019000476A (es) Anticuerpos especificos para la tau hiperfosforilada y sus metodos de uso.
IL283379A (en) Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof
JOP20200074A1 (ar) أجسام مضادة ضد tau واستخداماتها
MX395317B (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
MX2024011869A (es) Anticuerpos anti-tau y metodos de uso
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
MX2019011423A (es) Metodos de tratamiento de enfermedades neurodegenerativas.
MX393600B (es) Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
MX2017009038A (es) Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
EP3805390A4 (en) NAV1.7 MONOCLONAL ANTIBODY
EA201990253A1 (ru) Гуманизированные антитела против s100a9 и их применение
BR112018068803A2 (pt) método para purificação de proteína
AR117649A1 (es) Anticuerpos estabilizadores de trem2
EA202090891A1 (ru) Молекулы антител против cd138 и их применение
EA201992747A1 (ru) Антитела к fam19a5 и их применение
CL2018003283S1 (es) Automóvil (divisional solicitud 201800156).
EA202090330A1 (ru) Композиции и способы лечения расстройств, связанных со стрессом